Evidence map›Paper›PMID 28833898›Full record

ArticleBrain pathology (Zurich, Switzerland)2018

Hippocampal sclerosis, hippocampal neuron loss patterns and TDP-43 in the aged population.

Suvi R K Hokkanen, Sally Hunter, Tuomo M Polvikoski, Hannah A D Keage, Thais Minett, Fiona E Matthews, Carol Brayne, MRC CFAS and CC75C Study Group

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04244630 (Mitochondrial Capacity Boost in ALS), which is not on this map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04244630 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

TypeinterventionalSponsorDallas VA Medical CenterRan2023 to 2025Enrolled60ConditionsAmyotrophic Lateral Sclerosis (ALS)ArmsAntioxidants
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Co-pathologies modify hippocampal protein accumulation patterns in neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Neurodegeneration of White and Gray Matter in the Hippocampus with FXTAS.International journal of molecular sciences · 2023
    Article
  11. Article
  12. Hippocampal sclerosis of aging at post-mortem is evident on MRI more than a decade prior.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  13. Article
  14. Review
  15. Review
  16. A novel histological staging of hippocampal sclerosis that is evident in gray matter loss in vivo.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Suvi R K HokkanenInstitute of Public Health, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6520-1274
Sally HunterInstitute of Public Health, University of Cambridge, Cambridge, UK.ORCID 0000-0002-8063-6556
Tuomo M PolvikoskiInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
Hannah A D KeageCognitive Ageing and Impairment Neurosciences Laboratory, Social Work and Social Policy, University of South Australia, Adelaide, South Australia.
Thais MinettInstitute of Public Health, University of Cambridge, Cambridge, UK.
Fiona E MatthewsInstitute for Health and Society, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-1728-2388
Carol BrayneInstitute of Public Health, University of Cambridge, Cambridge, UK.
MRC CFAS and CC75C Study Group
University of Cambridge · GBNewcastle University · GBUniversity of South Australia · AU

Funding

Department of HealthMedical Research Council G0400074Medical Research Council G0502157Medical Research Council G0601022Medical Research Council G0900652Medical Research Council G1100540Medical Research Council G9901400Medical Research Council MC_U105292687Medical Research Council MC_UU_00002/12Medical Research Council MR/L022656/1Medical Research Council U.1052.00.013
6 · The paper itself

Abstract

Hippocampal neuron loss is a common neuropathological feature in old age with various underlying etiologies. Hippocampal sclerosis of aging (HS-Aging) is neuropathologically characterized by severe CA1 neuronal loss and frequent presence of transactive response DNA-binding protein of 43 kDa (TDP-43) aggregations. Its etiology is unclear and currently no standardized approaches to measure HS-Aging exist. We developed a semi-quantitative protocol, which captures various hippocampal neuron loss patterns, and compared their occurrence in the context of HS-Aging, TDP-43, vascular and tau pathology in 672 brains (TDP-43 staining n = 642/672, 96%) donated for the population-based Cambridge City over-75s Cohort and the Cognitive Function and Ageing Study. HS-Aging was first evaluated independently from the protocol using the most common criteria defined in literature, and then described in detail through examination of neuron loss patterns and associated pathologies. 34 (5%) cases were identified, with a maximum of five pyramidal neurons in each of over half CA1 fields-of-view (x200 magnification), no vascular damage, no neuron loss in CA2-CA4, but consistent TDP-43 neuronal solid inclusions and neurites. We also report focal CA1 neuron loss with vascular pathology to affect predominantly CA1 bordering CA2 (Fisher's exact, P = 0.009), whereas neuron loss in the subicular end of CA1 was associated with TDP-43 inclusions (Fisher's exact, P < 0.001) and high Braak stage (Fisher's exact, P = 0.001). Hippocampal neuron loss in CA4-CA2 was not associated with TDP-43. We conclude that hippocampal neuron loss patterns are associated with different etiologies within CA1, and propose that these patterns can be used to form objective criteria for HS-Aging diagnosis. Finally, based on our results we hypothesize that neuron loss leading to HS-Aging starts from the subicular end of CA1 when it is associated with TDP-43 pathology, and that this neurodegenerative process is likely to be significantly more common than "end-stage" HS-Aging only.

Indexed as

AgingAged, 80 and overDNA-Binding ProteinsFemaleHippocampusHumansInclusion BodiesMaleNeuronsSclerosisDNA-Binding ProteinsTARDBP protein, humanhippocampal sclerosishippocampusneuron losspopulation studyTDP-43

Identifiers

PMID28833898
PMCPMC6099461
OpenAlexW2745354339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.